Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash & Equivalents (2018 - 2026)

10x Genomics' Cash & Equivalents history spans 8 years, with the latest figure at $474.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 37.75% to $474.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $474.0 million, a 37.75% increase, with the full-year FY2025 number at $474.0 million, up 37.75% from a year prior.
  • Cash & Equivalents hit $474.0 million in Q4 2025 for 10x Genomics, up from $432.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TXG hit a ceiling of $622.0 million in Q2 2021 and a floor of $219.7 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $397.8 million across 5 years, with a median of $368.2 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: soared 83.01% in 2021 and later plummeted 62.59% in 2022.
  • Tracing TXG's Cash & Equivalents over 5 years: stood at $587.4 million in 2021, then plummeted by 62.59% to $219.7 million in 2022, then skyrocketed by 63.5% to $359.3 million in 2023, then dropped by 4.24% to $344.1 million in 2024, then surged by 37.75% to $474.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for TXG at $474.0 million in Q4 2025, $432.5 million in Q3 2025, and $397.7 million in Q2 2025.